IOVANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
IOVANCE BIOTHERAPEUTICS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$14.21+0.59 (+4.33%)
Close on Oct 19, 2026
- Market cap
- $6.40M
- P/E (TTM)
- –
- Dividend yield
- –
IOVANCE BIOTHERAPEUTICS, INC. revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amtagvi | $273.32M | $236.68M | $220.02M | $203.84M | $188.39M | $147.14M | $103.57M | – | – | – | – | 84.1% | +45.1% |
| Proleukin | $51.65M | $48.93M | $43.48M | $46.59M | $53.13M | $65.54M | $60.50M | $36.00M | $19.95M | $1.90M | $1.19M | 15.9% | -2.8% |
By region
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $321.33M | $280.97M | $259.01M | $246.72M | $238.13M | $209.56M | $161.04M | $87.85M | $30.03M | $0 | $0 | 98.9% | +34.9% |
| Non-US | $3.64M | $4.64M | $4.49M | $3.70M | $3.39M | $3.12M | $3.03M | $3.01M | $2.74M | $1.90M | $1.19M | 1.1% | +7.4% |
From the segment and revenue-disaggregation notes of Iovance Biotherapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.